Core Viewpoint - The Schall Law Firm is investigating claims against RxSight, Inc. for potential violations of securities laws following a significant decline in the company's stock price after disappointing financial results [1][2]. Financial Performance - RxSight reported a decline in sales of Light Delivery Devices (LDD) and light adjustable intraocular lenses (LAL), contributing to an overall revenue decrease [2]. - The company lowered its full-year guidance for 2025, citing "Adoption challenges over the last few quarters" as a primary reason for the stall in LDD sales [2]. - Following the announcement of these results on July 9, 2025, RxSight's shares fell by 37.8% [2]. Legal Investigation - The investigation by the Schall Law Firm focuses on whether RxSight made false or misleading statements or failed to disclose important information to investors [2].

Core Viewpoint - The Schall Law Firm is investigating Quipt Home Medical Corp. for potential violations of securities laws, particularly concerning misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Quipt issued false or misleading statements, particularly regarding a press release on May 21, 2025, related to an acquisition offer from Forager Capital Management [2]. - Forager Capital Management, a significant shareholder, has requested Quipt to retract its misleading statement about their offer to acquire 100% of Quipt's common shares at a price of $3.10 per share [2]. - Following the news of the investigation and the press release from Forager, Quipt's shares experienced a decline of over 8.5% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free discussion of their rights [3].

Core Viewpoint - The Schall Law Firm is investigating Bausch + Lomb Corporation for potential violations of securities laws, focusing on misleading statements and undisclosed information that may have affected investors [1][2]. Financial Performance - Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a significant decline compared to a net income of $24 million in the same period of the previous year [2]. - The company has lowered its full-year growth outlook, attributing part of this change to the recall of its enVista product [2].

Core Viewpoint - The Schall Law Firm is investigating SelectQuote, Inc. for potential violations of securities laws related to misleading statements and undisclosed information [1][2]. Investigation Details - The investigation centers on claims that SelectQuote may have issued false or misleading statements and failed to disclose critical information to investors [2]. - A DOJ False Claims Act was filed against SelectQuote on May 1, 2025, alleging that from 2016 to at least 2021, insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [2]. - Following the news of the investigation, SelectQuote's shares dropped by 16% on the same day [2].

Core Viewpoint - The Schall Law Firm is investigating ICU Medical, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether ICU Medical issued false or misleading statements and failed to disclose critical information to investors [2]. - An FDA warning letter dated April 22, 2025, highlighted that ICU Medical made multiple changes to its Medfusion Model 4000 Syringe Infusion Pump and CADD Solis VIP Ambulatory Infusion Pump, which could significantly impact the safety and effectiveness of these devices [2]. - The FDA classified the pumps as "adulterated" and "misbranded," indicating that modifications could significantly affect functionality, including infusion delivery profiles and alarm functionality, thereby altering the risk profile of the devices [2].